Convergence Pharmaceuticals Limited

Glaxo Group Limited

Sadie Vile

Diane Mary Coe

Brian Edgar Looker

Paul John Beswick

Robert James Gleave

Andrew Peter Cridland

Jag Paul Heer

Neville Hubert Nicholson

Lee William Page

Alister Campbell

Simon Edward Ward

Paul Martin Gore

Shuji Hachisu

Panayiotis Alexandrou Procopiou

Anthony William James Cooper

Simon Teanby Hodgson

Stefan Senger

David George Allen

Ashley Paul Hancock

David House

Steven Leslie Sollis

Nicolas Bertheleme

Nicholas Bertheleme

Caroline Wilson

Michael Joachim Kranz

Simon E Ward

The present invention relates to novel tetrazole compounds; to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Ca2.2 calcium channels is beneficial. Formula (I) wherein A is: (II) or (III)  

Tetrazole compounds as calcium channel blockers

The present invention relates to novel tetrazole compounds of Formula (I) wherein A is (II) or (III); to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Ca2.2 calcium channels is beneficial. wherein A is 

The present invention relates to novel piperazine derivatives; to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Ca2.2 calcium channels is beneficial.

3-pyridylcarbonyl-piperazinylsulfonyl derivatives

The present invention relates to novel piperazine derivatives (I); to processes for their preparation; to pharmaceutical compositions containing the derivatives; and to the use of the derivatives in therapy to treat diseases for which blocking the Ca2.2 calcium channels is beneficial.

Piperazine derivatives used as CAV2.2 calcium channel modulators

The present invention relates to amide compounds, processes for their preparation, pharmaceutical compositions containing these compounds and to their use in the treatment of disorders, conditions or disorders such as allergic disorders, inflammatory disorders and disorders of the immune system.

N-pyrazolyl carboxamides as CRAC channel inhibitors

The present invention relates to a compound which is N-(4-{4-[(6-butyl-8-quinolinyl)oxy]-1-piperidinyl}butyl)ethanesulfonamide and salts thereof, processes for its preparation, to compositions containing it and to its use in the treatment of various diseases, such as allergic rhinitis.

Compounds

Growing community of inventors

Harlow, United Kingdom

Sadie Vile